Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash & Current Investments (2018 - 2025)

Arcturus Therapeutics Holdings' Cash & Current Investments history spans 8 years, with the latest figure at $230.9 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 20.93% year-over-year to $230.9 million; the TTM value through Dec 2025 reached $230.9 million, down 20.93%, while the annual FY2025 figure was $230.9 million, 20.93% down from the prior year.
  • Cash & Current Investments reached $230.9 million in Q4 2025 per ARCT's latest filing, down from $235.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $466.8 million in Q1 2021 to a low of $230.9 million in Q4 2025.
  • Average Cash & Current Investments over 5 years is $322.2 million, with a median of $317.5 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 684.99% in 2021, then plummeted 42.57% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $370.5 million in 2021, then increased by 5.77% to $391.9 million in 2022, then decreased by 11.45% to $347.0 million in 2023, then fell by 15.84% to $292.0 million in 2024, then dropped by 20.93% to $230.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Cash & Current Investments are $230.9 million (Q4 2025), $235.4 million (Q3 2025), and $251.5 million (Q2 2025).